Know Cancer

or
forgot password
  • cancer clinical trials in new britain, CT

  • AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Fallopian Tube Cancer, Ovarian Cancer, Malignant Tumor of Peritoneum
    Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Leukemia
    Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Lung Cancer
    Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
    Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
    ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

    New Britain, Connecticut 06052
    Metastatic Colorectal Cancer
    Connect® MM- The Multiple Myeloma Disease Registry
    Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Multiple Myeloma
    Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Ovarian Mucinous Cystadenocarcinoma, Ovarian Mucinous Cystadenoma With Proliferating Activity, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Epithelial Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Epithelial Cancer, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Epithelial Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer
    Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage III or Stage IV Cancer of the Oropharynx That Can Be Removed By Surgery
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Head and Neck Cancer, Precancerous Condition
    Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Malignant Mesothelioma
    Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Cervical Cancer, Endometrial Cancer, Sarcoma
    Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Cervical Cancer
    Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Lung Cancer
    Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma
    Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
    Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Breast Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Colorectal Cancer
    Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Epithelial Cancer, Stage IIA Primary Peritoneal Cavity Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Epithelial Cancer, Stage IIB Primary Peritoneal Cavity Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Epithelial Cancer, Stage IIC Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
    Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
    Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Light Chain Deposition Disease, Smoldering Multiple Myeloma
    Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
    Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
    Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

    New Britain, Connecticut 06052
    Prostate Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
    Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Adenoma, Pancreatic Beta Islet Cell Carcinoma, Pancreatic Delta Cell Adenoma, Pancreatic Delta Cell Carcinoma, Pancreatic G-cell Adenoma, Pancreatic G-cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Recurrent Pancreatic Cancer, Somatostatinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
    Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
    Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer
    Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Head and Neck Cancer, Precancerous Condition
    A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
    Grove Hill Clinical Research, Grove Hill Medical Center, Urology Center of Grove Hill
    New Britain, Connecticut 06052
    Advanced Prostate Cancer, Prostatic Neoplasms
    Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Anxiety Disorder, Fallopian Tube Cancer, Fatigue, Nausea and Vomiting, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Cervical Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexuality and Reproductive Issues
    Patient Reported Symptoms in Ovarian Cancer (PRECISION)

    New Britain, Connecticut 06052
    Ovarian Cancer
    Study of Ruxolitinib in Pancreatic Cancer Patients

    New Britain, Connecticut 06052
    Metastatic Pancreatic Adenocarcinoma
    Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
    A Phase 1 Study of IPI-145 in Patients With Advanced Hematologic Malignancies

    New Britain, Connecticut 06052
    Hematologic Malignancies
    Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Colorectal Cancer
    A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

    New Britain, Connecticut 06052
    Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer
    Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Secondary Myelodysplastic Syndromes
    Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Sarcoma
    Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
    New Britain, Connecticut 06050
    Gestational Trophoblastic Tumor
    Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
    Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

    New Britain, Connecticut 06052
    Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
    Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumor
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Oligodendroglioma, Recurrent Adult Brain Tumor
    Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
    For information concerning this clinical site, please contact Nymox at 800-936-9669.
    New Britain, Connecticut 06052
    Prostate Cancer
    VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
    The Hospital of Central Connecticut
    New Britain, Connecticut 06050
    Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer